The present invention relates to the use of one or more cannabinoids in combination with psilocybin and/or psilocin for use in the prevention or treatment of psychological or brain disorders. Preferably the one or more cannabinoids are taken from the group cannabidiol (CBD)； cannabidiolic acid (CBDA)； tetrahydrocannbidivarin (THCV)； tetrahydrocannbidivarinin acid (THCVA)； cannabichromene (CBC)； cannabichromenic acid (CBCA)； cannabigerol (CBG) and cannabigerolic acid (CBGA).
